Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate



 According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated
Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
                and is Displacing Jevtana to Later-Line mCRPC

Downstream Cost Savings, Will Encourage EU5 Payers to Think Beyond the Price
Tag, Although Drug Cost Must Be Well Balanced Against Potential Uptake,
According to a New Report from Decision Resources

PR Newswire

BURLINGTON, Mass., March 18, 2013

BURLINGTON, Mass., March 18, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that, despite its recent market entry, Johnson &
Johnson/Janssen Biotech/Janssen Cilag's Zytiga has heavily penetrated surveyed
EU5 (France, Germany, Italy, Spain and the United Kingdom) oncologists'
second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC)
patients who have received prior treatment with docetaxel. Uptake of Zytiga is
especially high in France and the United Kingdom, where, on average,
approximately half of respondents' second-line patients are prescribed Zytiga.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Among respondents in most countries, Sanofi's Jevtana is more commonly used in
the third-line than the second-line setting, suggesting that second-to-market
Zytiga is displacing Jevtana to later-line mCRPC. In support of this finding,
most of those surveyed in all countries indicate that the recent launch of
Zytiga will influence a shift in prescribing of Jevtana toward later-line
mCRPC treatment in the next 12 months.

The new European Physician & Payer Forum report entitled The Dynamic Prostate
Cancer Landscape: How Will European Payer and Prescriber Attitudes Shape This
Competitive Market? finds that more than one-third of respondents in Germany
and Spain believe Zytiga's launch will significantly influence a shift in
Jevtana's prescribing, while almost one-quarter of those in Italy agree.
Zytiga's more favorable side-effect profile, convenient oral administration,
and mechanism of action likely explain why such a substantial percentage of
physicians expect this trend. At the end of 2015, despite the anticipated
approval of three new therapies—Medivation/Astellas Pharma's Xtandi,
Algeta/Bayer HealthCare's radium-223, and Takeda/Millennium's orteronel—Zytiga
will maintain its position as the favored second-line mCRPC therapy among
surveyed EU5 physicians.

This report also finds that, in addition to robust efficacy, therapeutic
innovation and demonstrable downstream cost savings are key market access
levers that will encourage EU5 payers to think beyond an emerging agent's
proposed price tag. Pharmaceutical innovation is key to reimbursement decision
making in Italy and Spain, and, in the former, inclusion on AIFA's innovative
drugs list ensures funding across regions.

"Savings in hospitalization and supportive care costs, as well as the societal
benefits of improving quality of life, will help encourage uptake within
countries following admission to reimbursement," said Decision Resources
Senior Director Rachel Webster, Ph.D. "Costs associated with management of
Jevtana's side effects may well have contributed to NICE's decision on its
lack of cost-effectiveness. Furthermore, the United Kingdom's value-based
pricing system, set to be implemented at the end of this year, will pave the
way for consideration of wider societal benefits and associated cost savings,
and the principles of this concept are increasingly evident across the EU5."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Website: http://www.decisionresources.com
Contact: Christopher Comfort, Decision Resources, +1-781-993-2597,
ccomfort@dresources.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement